EXHIBIT 99.1

Accretive Health Reports Second Quarter 2012 Financial Results

CHICAGO, August 8, 2012 — Accretive Health, Inc. (NYSE: AH), today reported financial results for the second quarter ended June 30, 2012.

Highlights for Second Quarter 2012

Mary Tolan, Accretive Health’s Founder and Chief Executive Officer, said, “We are pleased to announce the recent signing of our new five-year contract with Ascension Health, the nation’s largest Catholic and non-profit health care system. The new contract marks the continuation of our successful partnership between Ascension Health and Accretive Health which began in 2004. We look forward to entering a new era of creating value together through our partnership.

“We reluctantly settled the costly distraction of the Minnesota lawsuit. Although we strongly believe we would have prevailed in court, the reality of the litigation and political process today unfortunately makes settling this dispute the wiser course. We remain deeply committed to achieving the highest standards in confidentiality of patient healthcare information. Most importantly, entering into this settlement agreement allows our Company to put the litigation behind us.

The expense of responding to the Minnesota litigation, winding down our Minnesota operations and the operating costs from the distractions posed by these matters, negatively impacted our second-quarter

financial results and will naturally affect the year. However, we believe there has never been a greater need for our services and expertise. With the distraction of the Minnesota litigation now behind us we can turn greater attention to these opportunities and to building a great healthcare technology and services company dedicated to helping our clients solve some of healthcare’s most pressing challenges.”

Factors impacting the Quarter

The following matters had a negative impact of $14.6 million on the Company’s financial performance in the second quarter of 2012.

Financial Review

Second Quarter 2012

Net services revenue for the second quarter of 2012 grew by 28.9% to $236.7 million, an increase of $53.1 million over the second quarter of 2011.

Operating margin for the second quarter of 2012 was $45.3 million compared with $47.1 million for the second quarter of 2011.

Infused management and technology expense for the second quarter of 2012 was $26.0 million, or 11.0% of net services revenue, compared with $21.2 million, or 11.6% of net services revenue, for the second quarter of 2011.

Selling, general and administrative expenses were $20.6 million for the second quarter of 2012, or 8.7% of net services revenue, compared with $12.6 million, or 6.9% of net services revenue, for the second quarter of 2011.

During the second quarter of 2012, the Company had a net loss of $0.6 million, compared with net income of $8.6 million in the second quarter of 2011. After adjusting for non-cash employee stock-based compensation expenses on an after-tax basis, non-GAAP adjusted net income for the second quarter of 2012 was $3.0 million, compared with $11.8 million in the second quarter of 2011. Non-GAAP adjusted net income per diluted common share was $0.03 for the second quarter of 2012, as compared to the non-GAAP adjusted net income per diluted common share of $0.12 in the second quarter of 2011.

EBITDA for the second quarter of 2012 was $1.3 million, compared with $15.3 million for the second quarter of 2011. Included in these results were non-cash employee stock-based compensation expenses of

$5.9 million and $5.4 million for the second quarter of 2012 and the second quarter of 2011, respectively. After adjusting for these expenses, non-GAAP adjusted EBITDA for the second quarter of 2012 was $7.3 million, compared with $20.7 million for the second quarter of 2011. For the first two quarters of 2012, operating cash flow totaled $6.2 million, compared with negative operating cash flow of $28.5 million for the same period of 2011 primarily due to the timing of payments from customers and to vendors. For similar reasons free cash flow, defined as operating cash flow less capital expenditures and the acquisition of software, was a negative $4.0 million for the first two quarters of 2012, compared with negative free cash flow of $35.2 million for the same period of 2011.

At June 30, 2012, Accretive Health’s balance sheet remained strong with a total cash balance of $200.9 million, compared with $196.7 million at December 31, 2011.

Fiscal Year 2012 Guidance

Accretive Health is revising its guidance issued on May 9, 2012 for fiscal year 2012. As of today PCARR is $867 million to $884 million. Accretive Health is reaffirming its guidance that PCARR at year end will be in the range of $960 million to $1,005 million. Accretive Health is revising its guidance for 2012 net services revenue to be in the range of $948 million to $980 million reflecting the wind down of the remaining Minnesota clients.

The Company is revising its guidance for non-GAAP adjusted EBITDA for 2012 to be in the range of $50 million to $55 million. The following factors impacting 2012 non-GAAP adjusted EBITDA reflect an additional $15 million to $19 million of anticipated impact for the remainder of 2012 as set forth below:

We estimate that our existing contracts would have a run-rate adjusted EBITDA of $78 million to $82 million for the following year. New contracts signed between now and the end of the year would be additive.

Finally, the Company is revising its guidance for non-GAAP adjusted diluted earnings per share for the year ended December 2012 to be in the range of $0.23 to $0.27.

The Company continues to actively pursue new business opportunities, and will provide updates as appropriate.

Conference Call

Accretive Health’s management will host a conference call today at 7:30 a.m. CDT (8:30 a.m. EDT) to discuss its second quarter 2012 results and business outlook for fiscal year 2012. To participate, please dial 800-901-5241 (or 617-786-2963 outside the U.S. and Canada) using conference code number 70863029, or visit the Investor Relations section of Accretive Health’s web site at www.accretivehealth.com to access the live webcast. A replay will be available for one week following the conference call at 888-286-8010 (or 617-801-6888 outside the U.S. and Canada) using conference code number 55791212. A replay of the conference call will also be available online at www.accretivehealth.com.

About Accretive Health

Accretive Health partners with healthcare providers to help them more effectively manage their revenue cycles, strengthen their financial stability, and improve the quality of care they provide while reducing overall healthcare costs. Our people, processes and sophisticated integrated technology complement our clients’ existing resources to enhance results for patients, physicians and staff. For more information, please visit www.accretivehealth.com.

Safe Harbor

This document contains forward-looking statements, including statements regarding Accretive Health’s expectations for future financial and operational performance, expected growth, new services, profitability or business outlook, our new master professional services agreement with Ascension Health and our ability to enter into new supplement agreements with hospitals affiliated with Ascension Health, the effects of the ongoing investigations of our operating practices being conducted by various parties, our responses to these investigations and the impact of the Company’s settlement agreement with the Minnesota Attorney General, securities-related class action and derivative lawsuits filed against us and certain of our officers and directors, follow-on investigations and inquiries by government authorities, and other litigation matters, all of which involve risks and uncertainties. Our actual results and outcomes could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, as amended, filed with the SEC (File No. 001-34746), under the heading “Risk Factors”. The words “strive,” “objective,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “would,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying any of our forward-looking statements are reasonable, these expectations may prove to be incorrect and all of these statements are subject to risks and uncertainties. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections, or expectations prove incorrect, actual results, performance, financial condition, or events may vary materially and adversely from those anticipated, estimated, or expected.

All forward-looking statements included in this report are expressly qualified in their entirety by the foregoing cautionary statements. We wish to caution readers not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the uncertainties and factors described above, as well as others that we may consider immaterial or do not anticipate at this time. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown uncertainties and factors, including those described above. The risks and uncertainties described above are not exclusive, and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition or relationships with customers and potential customers, may emerge from time to time. We assume no, and we specifically disclaim any, obligation to update, amend, or clarify forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. We advise you, however, to consult any further disclosures we make on related subjects in our periodic reports that we file with or furnish to the U.S. Securities and Exchange Commission.

Accretive Health, Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

Accretive Health, Inc.

Condensed Consolidated Balance Sheets

Accretive Health, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

Explanation of Operational Metrics

We define Projected Contracted Annual Revenue Run-Rate (PCARR) as the expected total net services revenue for the subsequent 12 months for all healthcare providers for which we are providing services that are under contract. We believe that our Projected Contracted Annual Revenue Run-Rate is a useful measure of our overall business volume at a particular point in time and of changes in the volume of business over time because it eliminates the time impact associated with the signing of new contracts during a quarterly or annual period.

PCARR is calculated by accumulating our estimates of the next 12 months’ base fees, cost saving sharing credits and incentive payments for each contract in place at the reporting date. Our base fee estimate is based on the contractual agreement with each customer relating to the services that we will provide and the costs that the customer was incurring for completing such activities prior to entering into its agreement with us. Our estimates for cost sharing credits and incentive payments are based on the Company’s prior experiences regarding the level of cost reductions and increases in net revenue yield and its management’s experience regarding potential reductions in total medical cost for a defined patient population, which are likely to be earned during each year a contract is in place given the level of infused management as well as the degree to which we have implemented our technology. We update these estimates regularly to incorporate changes in activities under management for a specific contract, and changes in our overall experience with our portfolio of contracts. There were no significant changes in our overall assumptions used in the calculation of PCARR as of June 30, 2012.

All of our contracts have “evergreen” provisions that extend the term of our services automatically unless the customer provides notification of non-renewal. Therefore, unless a notice of non-renewal has been received, our PCARR calculation assumes that each contract in place at the reporting date will continue for at least the next 12 months. In the event that we receive a non-renewal notice from a customer, we reduce the PCARR calculation by the amount associated with that specific contract for any periods after the contract’s then current end date. At June 30, 2012, PCARR includes approximately $197 million related to periods subject to assumed contract extensions, mostly relating to the Ascension master services agreement that is due for renewal in December, 2012. As announced in the Company’s filing on Form 8K issued on August 6, 2012, the Company entered into a new 5 year services agreement with Ascension.

PCARR is not a projection of expected revenues for specific future periods because any such projection would also need to include the additional revenue resulting from any future contracts signed with new customers subsequent to the reporting date. Further, actual future revenues from existing customers may differ from the projected amounts used for purposes of calculating PCARR because the scope of services provided to existing customers may change and the incentive fees we earn may be more or less than we estimate depending on our ability to achieve projected increases in our customers’ net revenue yield and projected reductions in total medical cost of the customers’ patient population.

We define the contracting phase of our sales process as the final stage when we have reached general agreement with the potential customer on scope, business terms and conditions under which our services will be provided and the written contract is in the process of being negotiated and finalized for execution.

Explanation and Use of Non-GAAP Financial Measures

To provide investors with greater insight and a better understanding of how our management and board of directors analyze our financial performance and make operational decisions, we supplement our consolidated financial statements that are presented on a GAAP basis in this press release with the following non-GAAP financial measures: adjusted EBITDA, free cash flow, adjusted net income, and adjusted net income per diluted common share.

These non-GAAP financial measures should not be considered in isolation; they are in addition to, and are not a substitution, for financial performance measures under GAAP. These non-GAAP financial measures may be different from non-GAAP measures used by other companies. Further, we may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations since they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP.

We define non-GAAP adjusted EBITDA as net income (loss) before net interest income (expense), income tax expense (benefit), depreciation and amortization expense and share based compensation expense. We define non-GAAP adjusted net income as net income (loss) before share based compensation expense, net of the estimated tax impact of such expense. We define non-GAAP adjusted net income per diluted common share as non-GAAP adjusted net income applicable to common shareholders divided by the weighted average fully diluted common shares outstanding during the period as computed in accordance with GAAP.

We use non-GAAP adjusted EBITDA:

We believe that non-GAAP adjusted EBITDA, non-GAAP adjusted net income, and non-GAAP adjusted net income per diluted common share are useful to investors in evaluating our operating performance for the following reasons:

We understand that, although measures similar to non-GAAP adjusted EBITDA and non-GAAP adjusted net income are frequently used by investors and securities analysts in their evaluation of companies, these

measures have limitations as an analytical tool, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under GAAP. Some of the limitations of these specific non-GAAP financial measures are:

Non-GAAP Adjusted EBITDA

The following table presents a reconciliation of non-GAAP adjusted EBITDA to net income, the most comparable GAAP measure (unaudited; in thousands):

Net interest income represents earnings from our cash and cash equivalents. No debt or other interest-bearing obligations were outstanding during any of the periods presented.

Non-GAAP Adjusted Net Income (Loss) and Non-GAAP Adjusted Net Income per Diluted Common Share

The following table presents a reconciliation of non-GAAP adjusted net income to net income, the most comparable GAAP measure, details how we calculate non-GAAP adjusted net income per diluted common share, and reconciles non-GAAP adjusted net income per diluted common share to fully diluted earnings per common share, the most comparable GAAP measure (unaudited; in thousands, except share and per share amounts):

Contacts:

For investors

Gary Rubin, 312-324-7813

Senior Director of Finance and Investor Relations Officer

investorrelations@accretivehealth.com

For Media

Kekst and Company

Ruth Pachman, 212-521-4891